KIORA PHARMACEUTICALS INC
No SEC Form 4 filings for $KPRX in the last 30 days.
See all $KPRX insider activity →KIORA PHARMACEUTICALS INC (KPRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex101-exclusivelicenseagre.htm EX-10.1 Document CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS A TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [***] INDICATES THAT INFORMATI
Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q2 2026 results and a corporate update. It said Phase 2 ABACUS-2 enrollment for KIO-301 advanced into the higher-dose cohort and Phase 2 KLARITY enrollment for KIO-104 continued in the higher-dose group. Cash and short-term investments were about $16.8M, expected to fund operations into late 2028, and it secured up to $24.0M gross from a private placement.
KIORA PHARMACEUTICALS INC (KPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-pressreleasejune3020.htm EX-99.1 Document Exhibit 99.1 Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update ENCINITAS, Calif.—August 7, 2026 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today reported financial results
Over the past 7 days, alphai's AI scored 1 news story mentioning KPRX (KIORA PHARMACEUTICALS INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent KPRX coverage spans financial news, corporate actions and earnings.
The agreement grants CKD exclusive rights to develop and commercialize Kiora's retinal disease IP, potentially providing Kiora with upfront and milestone payments.
Near-term trading focus is funding runway and clinical execution milestones, with dilution risk from the private placement and warrant structure.
Near-term trading focus is capital runway plus financing overhang, alongside updated Phase 2 enrollment timelines for KIO-301 and KIO-104.
The filing is primarily corporate-governance/compensation related, updating the company’s equity incentive framework and related officer/director arrangements.
The positive Phase 1 trial results for KIO-301 in retinitis pigmentosa and ongoing Phase 2 trial suggest potential near-term upside for KPRX.
alphai scores every news story that mentions KPRX with an AI model for sentiment and relevance, and aggregates insider trades from KIORA PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
KIORA PHARMACEUTICALS INC (KPRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex101-exclusivelicenseagre.htm EX-10.1 Document CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS A TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [***] INDICATES THAT INFORMATI
1 min readKiora Pharmaceuticals (NASDAQ: KPRX) reported Q2 2026 results and a corporate update. It said Phase 2 ABACUS-2 enrollment for KIO-301 advanced into the higher-dose cohort and Phase 2 KLARITY enrollment for KIO-104 continued in the higher-dose group. Cash and short-term investments were about $16.8M, expected to fund operations into late 2028, and it secured up to $24.0M gross from a private placement.
6 min readKIORA PHARMACEUTICALS INC (KPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-pressreleasejune3020.htm EX-99.1 Document Exhibit 99.1 Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update ENCINITAS, Calif.—August 7, 2026 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today reported financial results
6 min readKIORA PHARMACEUTICALS INC (KPRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 exhibit101-2024equityplana.htm EX-10.1 Document KIORA PHARMACEUTICALS, INC. 2024 Equity Incentive Plan (As Amended on June 10, 2026) ARTICLE 1. INTRODUCTION The Plan was adopted by the Board on March 14, 2024, and will become effective immediately upon its approval by t
3 min readKiora Pharmaceuticals announced the publication of its Phase 1 ABACUS-1 study results for KIO-301 in Nature Medicine, confirming the drug's safety and feasibility in late-stage retinitis pigmentosa patients. KIO-301, a molecular photoswitch, aims to restore light responsiveness regardless of genetic mutation. Building on these positive findings, the company has initiated a randomized, controlled Phase 2 clinical trial (ABACUS-2) to further evaluate higher doses and functional visual improvements.
4 min readKiora Pharmaceuticals ( NASDAQ:KPRX ) , a clinical-stage biotech focused on therapies for vision loss and retinal diseases, released its second-quarter results on August 8, 2025. The most notable news was the absence of recognized revenue ( GAAP ) , which came in below the $0.75 million analyst ...
2 min readKiora Pharmaceuticals (KPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 min read
